The Lille University Hospital developped a research objective common to all the services which took care of patients, "suspected patient", "possible case", "probable case" or "confirmed case" infected with SARS-CoV-2 by constituting a prospective and a retrospective observational cohort which allowed pooling and sharing the resources and data collected. In the next two years the prospective cohort will allow to continue inclusions in a standardized way mainly for the constitution of a negative control group (excluded cases), to collect biological samples which had not been collected in the retrospective cohort so that the pathophysiology of the COVID-19 will be better apprehended as for example the inflammatory response to the viral infection. Finally in case of a second epidemic wave in the Hauts De France, it seems essential to have a defined research protocol which had already received all the necessary authorizations to guarantee cutting-edge (or quality ) research in a center like the Lille University Hospital.The aim objective of this study is to identify predictive factors of mortality to day 28 infection to SARS-CoV-2 for patients under medical care for the COVID-19 in the Lille University Hospital thanks to the constitution of an epidemiological, clinical, biological, immunological, genetic, microbiological, anatomopathologic, radiological, therapeutic database and so record the results of functional exploration exams.
This is a retrospective and prospective observational monocentric cohort study designed to identify predictors of mortality on day 28 in patients treated at the Lille University Hospital for COVID-19.
Study Type
OBSERVATIONAL
Enrollment
757
Hop Claude Huriez Chr Lille
Lille, France
Number of patients "confirmed cases" of SARS-CoV-2 infection who died at D28 of inclusion
Identify predictors of mortality at day 28 in patients treated at the Lille University Hospital for COVID-19
Time frame: At 28 days
Correlation between Infection characteristics of patients at inclusion and all predictors for Covid-19
Describe, at inclusion, the epidemiological, clinical, biological, immunological, genetic, microbiological, radiological, therapeutic characteristics and the results of functional explorations of patients hospitalized in our center with SARS-CoV-2 infection.
Time frame: At inclusion (day 0)
Correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for Covid-19
Describe the evolution of the characteristics the epidemiological, clinical, biological, immunological, genetic, microbiological, anatomopathological, radiological, therapeutic characteristics and the results of functional explorations of patients hospitalized in our center with SARS-CoV-2 infection.
Time frame: At inclusion ( day 0) ,at day 1 , day3±1, Day 5±1, day 7±1, day 9±2, day14±2, day30±3, at months 3±7 days and at months6±7days or until death
Positivity for Covid-19 patients performed and all predictors for Covid-19
The diagnosis of disease is excluded or confirmed by qRT-PCR SARS-CoV-2 (respiratory samples, blood, stool...) and/or serology.
Time frame: At inclusion (day 0)
Correlation between hospitalisation and all predictors for Covid-19
Identify epidemiological, clinical, radiological, biological, immunological and genetic predictors of hospitalization in patients with SARS-CoV-2 infection.
Time frame: At inclusion( Day 0)
Correlation between risk factors measured at D0 for severe CoV-2 SARS infection and all predictors for Covid-19
Identify epidemiological, clinical, radiological, biological, immunological and genetic predictors of sévère SARS-CoV-2 infection.
Time frame: At 28 day
Correlation between overall survival at Day 28 and all predictors for Covid-19
Identify epidemiological, clinical, radiological, biological, immunological, genetic and therapeutic predictors of survival in patients with SARS-CoV-2 infection.
Time frame: At 28 day
Cumulative incidence of at least one complication related to COVID 19
Death is a concurrent risk.
Time frame: during hospitalization or during outpatient follow-up of "confirmed case" patients at Lille University Hospital (maximum observation period 6 months).
Cumulative incidence of the thrombosis complication related to COVID 19
Death is a concurrent risk.
Time frame: during hospitalization or during outpatient follow-up of "confirmed case" patients at Lille University Hospital (maximum observation period 6 months).
All type of co-infections
Describe viral (other than SARS-CoV-2), bacterial and fungal co-infections in patients admitted for COVID disease 19. The appropriateness of the co-infection search is at the discretion of the clinician to fit the patient's history and clinical presentation
Time frame: At 6 months
Alteration of microbiota
alterations in respiratory and digestive microbiotes and their evolution potentially associated with bacterial or fungal superinfection in the most severe patients
Time frame: At 6 months
Biobanking for further analyses such as SARS-CoV2 studies
Time frame: At 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.